Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated Interferon Alfa-2b vs Interferon Alfa in Childhood Essential Thrombocythemia
NCT04226950Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2020
- Primary completion
- Oct 2024
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of peginterferon alfa-2b in essential thrombocythemia (ET), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Jan 2020; status: recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT04226950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04226950.